Accéder au contenu
MilliporeSigma
Toutes les photos(1)

Key Documents

390585

Sigma-Aldrich

Suberohydroxamic acid

95%

Synonyme(s) :

N,N′-Dihydroxyoctanediamide, SBHA, Suberoyl bis-hydroxamic acid

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme


About This Item

Formule linéaire :
[-(CH2)3CONHOH]2
Numéro CAS:
Poids moléculaire :
204.22
Numéro MDL:
Code UNSPSC :
12352100
ID de substance PubChem :
Nomenclature NACRES :
NA.22

Niveau de qualité

Pureté

95%

Pf

153-155 °C (lit.)

Groupe fonctionnel

amine

Chaîne SMILES 

ONC(=O)CCCCCCC(=O)NO

InChI

1S/C8H16N2O4/c11-7(9-13)5-3-1-2-4-6-8(12)10-14/h13-14H,1-6H2,(H,9,11)(H,10,12)

Clé InChI

IDQPVOFTURLJPT-UHFFFAOYSA-N

Actions biochimiques/physiologiques

Suberoyl bis-hydroxamic acid (SBHA) is a Histone deacetylase (HDAC) inhibitor. SBHA inhibits the activity of HDAC1 and HDAC3 with IC50 values of 250 and 300 nM, respectively. SBHA inhibits proliferation, and induces apoptosis in several cancer cell lines. SBHA has been shown to activate Notch signaling in medullary thyroid carcinoma (MTC) cells.

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable


Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Vous ne trouvez pas la bonne version ?

Si vous avez besoin d'une version particulière, vous pouvez rechercher un certificat spécifique par le numéro de lot.

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 4

1 of 4

Mohamed Rahmani et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 20(18), 4849-4860 (2014-07-30)
The aim of this study is to explore the efficacy and define mechanisms of action of coadministration of the PI3K/mTOR inhibitor BEZ235 and pan-HDAC inhibitor panobinostat in diffuse large B-cell lymphoma (DLBCL) cells. Various DLBCL cells were exposed to panobinostat
Jiansen Li et al.
Oncology reports, 37(1), 458-464 (2016-12-23)
Anaplastic thyroid cancer (ATC), usually derived from well-differentiated thyroid cancers is one of the most lethal human endocrine malignancies. In the present study, we report that in human ATC tumor tissue samples exist undetectable Notch1 and the active Notch1 intracellular
Li Ning et al.
The oncologist, 13(2), 98-104 (2008-02-29)
Medullary thyroid carcinoma (MTC) is a neuroendocrine (NE) malignancy that frequently metastasizes and has limited treatments. We recently reported that ectopic expression of Notch-1 in human MTC cells suppresses growth. The objective of this study was to evaluate the ability
Shuang Chen et al.
Blood, 124(17), 2687-2697 (2014-09-12)
Bim contributes to resistance to various standard and novel agents. Here we demonstrate that Bim plays a functional role in bortezomib resistance in multiple myeloma (MM) cells and that targeting Bim by combining histone deacetylase inhibitors (HDACIs) with BH3 mimetics
Denisa Hrckova Drozdkova et al.
Anticancer research, 40(9), 4979-4987 (2020-09-04)
Multiple myeloma is a highly heterogeneous disease of clonal plasma cells. Histone deacetylase (HDAC) inhibitors are promising anticancer drugs but their precise mechanisms of actions are not well understood. Cell-cycle regulation and pro-apoptotic effects of two histone deacetylase inhibitors, suberohydroxamic

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique